After re-reading the trial protocol it seems that when the full...

After re-reading the trial protocol it seems that when the full details are released on the current trial there should be enough information to show whether the drug actually works well enough on humans from my understanding.

Can anyone help on whether the details below if successful would be enough for a big pharma to get involved (especially the secondary endpoint)?

Primary Endpoint
1. Safety
2. Pharmacokinetics single dose
3. Pharmacokinetics with and without meals

Secondary Endpoint

1. Pharmacodynamics via a glucose test



Below is an old article from 2005 on DIA and big pharma interest.

Dia-B Tech catches global pharmaceutical eye
By Rebecca Urban
January 24, 2005

Former federal health minister Michael Wooldridge chairs Dia-B Tech.

Medical research company Dia-B Tech, which lists on the Australian Stock Exchange today, is already attracting interest from global pharmaceutical companies wanting to be involved in developing its potential diabetes treatments.

Paul Zimmet, who will manage two of Dia-B Tech's projects, said the company had been approached by a global pharmaceutical group and one of Europe's largest biotechnology companies about forming a partnership.

One company has sent representatives to Australia to investigate its Type-2 diabetes product ISF402, a naturally occurring peptide that has been shown to enhance the action of insulin and to lower blood glucose levels in rats.

"We have a very open strategy and are willing to look at whatever the best deal is that comes along," Professor Zimmet said. "We could joint-venture or we could do a licensing deal."

Negotiations are at early stage, but Professor Zimmet's project is in a much better position than a few years ago, when the September 11 terrorist attacks in the US in 2001 - and subsequent crash of sharemarkets around the world - caused a key investor to withdraw plans to put in more than a $1 million in funding.

That same investor, Cardia Technologies, later took the project on as a wholly owned subsidiary, calling it Dia-B Tech.

Dia-B Tech, chaired by former federal health minister Michael Wooldridge, issued 30 million shares at 20 ¢ each, raising $6 million. Investors were unfazed that none of the four projects - targeting Type 1 and 2 diabetes and diabetes complications - have yet to be tested in humans, and the offer was heavily oversubscribed.

Professor Zimmet said the company was dealing with a disease that affected more than 190 million people around the world.

Dia-B Tech will operate with a virtual structure to minimise corporate costs, and is outsourcing much of its research and development. It plans to have ISF402 in human trials by the middle of this year.